Scalp psoriasis presents as a significant burden to patients due to the difficult-to-treat nature of the site.

Data suggest discussions about patient-preferred topical formulation may be a way to improve patient quality of life and increase treatment adherence.

Additionally, UVB and excimer phototherapy via handheld device or with the addition of a blow dryer to separate the hair has been efficacious in clearing of scalp plaques.

Etanercept, adalimumab, infliximab, brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, risankizumab, mirikizumab, ustekinumab, and apremilast all have demonstrated varying levels of efficacy in the scalp and are suitable first-line options for patients with scalp plaques plus whole-body psoriasis.

A practical treatment algorithm, derived from the most up-to-date empirical evidence, is also presented within this paper for mild-to-moderate scalp psoriasis, severe scalp psoriasis, and scalp psoriasis with moderate-to-severe whole-body involvement.